89151-45-1

Usage

Uses

Used in Organic Synthesis:
1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is used as an intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is used as a key intermediate in the development and synthesis of various drugs and bioactive molecules. Its presence in the molecule can influence the pharmacokinetic and pharmacodynamic properties of the final drug, contributing to improved efficacy, selectivity, and safety profiles.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is employed as a starting material or a building block for the design and synthesis of novel drug candidates. Its unique structural features enable researchers to explore new chemical space and develop innovative therapeutic agents with potential applications in various disease areas.
Used in Drug Development:
1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is utilized in drug development processes to optimize the chemical structure of drug candidates. Its presence can enhance the drug's stability, solubility, and bioavailability, which are critical factors in the development of effective and safe pharmaceuticals.
Used in Chemical Libraries:
1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is also used in the creation of chemical libraries for high-throughput screening. These libraries contain a diverse set of compounds that can be screened against biological targets to identify potential drug candidates with novel mechanisms of action.

InChI:InChI=1/C19H29NO5S/c1-15-5-7-17(8-6-15)26(22,23)24-14-11-16-9-12-20(13-10-16)18(21)25-19(2,3)4/h5-8,16H,9-14H2,1-4H3

Upstream product

• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 142247-37-8 4-(3-ethoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 252918-94-8 1-(tert-butoxycarbonyl)-4-[2-phenoxyethyl]piperidine 
• 718610-53-8 N-tert-butoxycarbonyl-4-[2-(4-methylthiophenylthio)ethyl]piperidine 
• 833491-25-1 tert-butyl 4-[2-({1-[(benzyloxy)carbonyl]piperidin-4-yl}sulfonyl)ethyl]piperidine-1-carboxylate 
• 1092513-09-1 tert-butyl 4-{2-[(2-{[(3-methoxybenzyl)amino]carbonyl}-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)methoxy]ethyl}piperidine-1-carboxylate 
• 167143-59-1 1-t-butoxycarbonyl-4-(2-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}ethyl)piperidine 
• 1360625-64-4 4-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)isoquinoline hydrochloride 
• 1360684-77-0 4-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)isoquinoline 
• 1360625-63-3 3-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)quinoline hydrochloride 
• 1360684-76-9 3-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)quinoline 
• 1360625-60-0 4-[2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

PROTEIN DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

SMARCA DEGRADERS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/o

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma

The tropical diseases human African trypanosomiasis, Chagas disease, and the various forms of leishmaniasis are caused by parasites of the family of trypanosomatids. These protozoa possess a unique redox metabolism based on trypanothione and trypanothione reductase (TR), making TR a promising drug target. We report the optimization of properties and potency of cyclohexylpyrrolidine inhibitors of TR by structure-based design. The best inhibitors were freely soluble and showed competitive inhibition constants (Ki) against Trypanosoma (T.) brucei TR and T. cruzi TR and in vitro activities (half-maximal inhibitory concentration, IC50) against these parasites in the low micromolar range, with high selectivity against human glutathione reductase. X-ray co-crystal structures confirmed the binding of the ligands to the hydrophobic wall of the “mepacrine binding site” with the new, solubility-providing vectors oriented toward the surface of the large active site.

The impact of the halogen bonding on D2 and 5-HT1A/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties

A series of azinesulfonamides of long-chain arylpiperazine derivatives with semi-rigid alkylene spacer was designed, synthesized, and biologically evaluated using in vitro methods for their affinity for dopaminergic D2 and serotoninergic 5-HTs

AD-35 preparation technology

The invention discloses a new preparation method of a benzodioxole derivative (AD-35) shown by the formula (I). The method comprises the following steps: with piperic acid as a raw material, performing bromination, esterification, cyaniding, cyclopropane

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS

The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Synthesis and evaluation of amide, sulfonamide and urea-benzisoxazole derivatives as potential atypical antipsychotics

In this paper, we report the optimization of a series of novel, potential antipsychotic derivatives combining potent dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptor affinities. The pharmacological features of compound 27 are a high affinity for dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptors. Moreover it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity associated with chronic treatment) and hERG channels (to reduce the incidence of torsade des pointes). Furthermore, compound 27 inhibited apomorphine-induced climbing, MK-801-induced hyperactivity and DOI-induced head twitch without observable catalepsy at the highest dose tested in mice. Taken together, among the amide derivatives, we identified compound 27 as a potential antipsychotic lead candidate.